CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding to tumor targets and the CD3 protein on cancer-killing T cells at the same time. However, development of T-cell engagers has been limited due to challenges with efficacy and safety.
To address these challenges, we have developed a T-cell engager platform that includes novel CD3-binding antibodies to expand the therapeutic window for this modality, costimulatory building blocks to enhance efficacy for difficult-to-treat cancers, and discovery capabilities to broaden the range of T-cell engagers to difficult tumor targets. This work yielded a comprehensive toolkit to enable custom design and optimization of molecules based on a target product profile.
Today, we announced an upcoming poster presentation on our T-cell engager platform at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Details on our poster presentation at SITC are as follows:
Title: Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release
Abstract Number: 1291
Date and Time: Friday, November 8 from 9:00 a.m. to 7:00 p.m. CST
Location: Exhibit Halls A B George R. Brown Convention Center or online
Download the poster on November 8, 2024.